Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients100

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients33

Views

Views
December 20255
January 20264
February 20260
March 202611
April 20263
May 20267
June 20263
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States15
Mexico3
Argentina2
Angola1
Brazil1
Germany1
Algeria1
Ecuador1
Egypt1
Spain1
 

Top cities views

Views
Los Angeles4
Buenos Aires2
Ashburn1
Bloomfield1
Damanhur1
Denver1
Gate City1
Guayaquil1
Gustavo Adolfo Madero1
Istanbul1